Pancreatitis Clinical Trial
Official title:
A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis
The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is a common cause of
morbidity for which there is no known pharmacologic prophylaxis. Post-ERCP pancreatitis is
thought to be caused by several factors, including intraductal pressure, multiple duct
injections with contrast, and neural arc reflexes. Lidocaine is a safe, inexpensive class IV
antiarrhythmic that has topical anesthetic effects, inhibits trypsin activity, and may
potentially prevent post-ERCP pancreatitis by injection directly into the pancreatic duct at
the time of ERCP. Lidocaine has been shown to inhibit phospholipase A2, a key pancreatic
enzyme, interrupt local arc reflexes to stop neuronal transmission, and to dampen GI tract
mucosal reflexes to prevent high ductal pressure.
The key objective of this study is to determine if injection of lidocaine is beneficial in
preventing post-ERCP pancreatitis. Subjects will be randomized to study group or control
group in an equal ratio. The physicians performing the ERCP will be unaware of the treatment
group to which patients have been assigned. Study arm will receive contrast agent Diatrizoate
60% (5 ml) diluted with lidocaine 2% (5 ml) during ERCP. Control arm will receive contrast
agent Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) during ERCP. Diatrizoate
diluted with normal saline is the standard of care. Patients will be contacted 1 day and 1
week post-ERCP to assess for symptoms of pancreatitis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03609944 -
SpHincterotomy for Acute Recurrent Pancreatitis
|
N/A | |
Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
Completed |
NCT01441492 -
Pancreas Resection With and Without Drains
|
N/A | |
Recruiting |
NCT02196935 -
Los Angeles Prospective GI Biliary and EUS Series
|
||
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01545167 -
The North American Pancreatitis Study
|
N/A | |
Completed |
NCT04168801 -
Early Oral Refeeding in Mild Acute Pancreatitis
|
N/A | |
Recruiting |
NCT03334708 -
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
|
||
Completed |
NCT01824186 -
Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy
|
N/A | |
Terminated |
NCT00428025 -
Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients
|
Phase 4 | |
Completed |
NCT00639314 -
Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT00160836 -
Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter
|
Phase 1 | |
Completed |
NCT00121901 -
Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?
|
Phase 3 | |
Completed |
NCT00999232 -
Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube
|
Phase 4 | |
Terminated |
NCT00419549 -
Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05095831 -
EUS Shear Wave for Solid Pancreatic Lesions.
|
||
Completed |
NCT03601325 -
Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
|
||
Not yet recruiting |
NCT06133023 -
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
|
N/A | |
Withdrawn |
NCT02465138 -
A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis
|
Phase 4 | |
Recruiting |
NCT02971475 -
ESWL Versus ESWL and Endoscopic Treatment
|
N/A |